BioSpace News Archive

HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, today announced the appointments of Lisa M. Coussens, Ph.D., and Ronald Wek, Ph.D., to its scientific advisory board.

OpenEye Scientific and Sygnature Discovery – a world-leading integrated discovery and pre-clinical solutions provider – today announced the adoption of OpenEye’s Orion™ platform to power Sygnature’s computational efforts in molecular design drug discovery solutions.

DarioHealth Corp., a pioneer in the global digital therapeutics market, announced the appointment of Chris Chan as Senior Vice President of Employer Sales.

OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer today announced the pricing of an underwritten public offering of 7,711,284 shares

AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities. Lilly’s Phase 3 BLAZE-2 COVID-19 prevention trial was conducted in partnership with the National Institute of Allergy and Infe

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced the pricing of an underwritten public offering of 4,848,485 common shares at a public offering price of $24.75 per share.

Thomas Scientific, the largest pure-play distributor of scientific products in the US, announced the launch of its Molecular Diagnostics business unit dedicated to serving the nation’s independent testing and reference laboratories.

Turn Therapeutics, a biotechnology company specializing in advanced wound care and infection control, today announced the initiation of a two-part, four-arm, human safety and efficacy trial for its flagship product, Hexagen, to be used in the fight against COVID-19.

Chiesi USA (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), has announced the internal appointments of Jason Beyer as VP and Business Unit Leader of the Neonatology and Cystic Fibrosis Business Unit and Jay Meyer as VP and Business Unit Leader of the Cardiovascular Hospital Business Unit. In these roles, Mr. Beyer and Mr. Meyer will report directly to Jon Zwinski,

FARE, the world’s leading non-governmental organization engaged in food allergy advocacy and the largest private funder of food allergy research, has awarded two competitive grants to partner institutions that will bolster FARE’s 2020 expansion of the FARE Clinical Network, powering advances in food allergy research.